Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00149643 · ClinicalTrials.gov registry record · Phase 2
Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence
A Phase 2 study of Depressive Disorder, Major and Cannabis Abuse, sponsored by University of Pittsburgh.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT00149643 is a Phase 2 study of Depressive Disorder, Major and Cannabis Abuse that has completed, run by University of Pittsburgh. The registered enrollment target is 70 participants, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (71% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00149643, a Phase 2 study of Depressive Disorder, Major and Cannabis Abuse, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major depressive disorder. The purpose of this study is to determine the effectiveness of fluoxetine in treating adolescents and young adults diagnosed with both major depressive disorder and marijuana dependence.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Fluoxetine
Study Locations (1)
Pennsylvania
- Department of Psychiatry - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00149643
The ClinicalTrials.gov registry entry for NCT00149643 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 241-participant average among 52 other Depressive Disorder, Major trials with a reported enrollment target (71% lower). The listed sponsor is University of Pittsburgh, which has 1,238 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Depressive Disorder, Major appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00149643 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00149643 about?
NCT00149643 is a clinical study titled "Effectiveness of Fluoxetine in Young People for the Treatment of Major Depression and Marijuana Dependence". Adolescents who are diagnosed with major depressive disorder are often also diagnosed with marijuana dependence. Fluoxetine is an antidepressant medication currently used to treat young people who are diagnosed with major depressive disorder. The purpose of this study is to determine the effectivene...
What is the current status of trial NCT00149643?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2004-09. Estimated completion is 2012-12.
What conditions does trial NCT00149643 study?
This clinical trial studies the following conditions: Depressive Disorder, Major, Cannabis Abuse.
What interventions are being tested in trial NCT00149643?
The interventions under investigation include: Placebo (OTHER), Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00149643?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00149643 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Depressive Disorder, Major
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
RECRUITING · Phase 2
-
Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation
RECRUITING · Phase 2
-
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
RECRUITING · Phase 2
-
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
RECRUITING · Phase 2
-
Individualized Functional Connectivity Targeting in aiTBS for Depression
ACTIVE NOT RECRUITING · Phase 2
-
OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult Females
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.